Abstract:Objective To study the immunological effects of combined immunization of mice with a DNA vaccine and a peptide vaccine consisting of multiple epitopes of latent membrane protein 2(LMP2)from Epstein-Barr virus(EBV).Methods BALB/c female mice were randomly divided into four groups.Group 1mice were immunized with a DNA vaccine delivered by major capsid protein L1of human papillomavirus(HPV)(pcDNA3.1(+)/HPVL1-EBV LMP2multiepitope.i.e.pcHPVL1-EBV LMP2).Group 2mice were immunized with the DNA vaccine and a peptide vaccine consisting of multiple epitopes of EBV LMP2.Group 3was immunized with pcDNA3.1(+)without the target gene(control DNA vaccine)while Group 4was immunized with an irrelevant peptide(control peptide vaccine).The DNA vaccine was injected intramuscularly while the peptide vaccine was injected subcutaneously.The immunization schedule was repeated 4 times at 2-week intervals.Seven weeks after immunization,serum samples from immunized mice were collected to detect EBV-specific IgG,IgA,and HPV L1-specific IgG using ELISA.Nine weeks after immunization,EBV-specific IgG subclass(IgG1and IgG2a)antibodies in serum were detected,and the cytotoxic activity of spleen cells from immunized mice was determined using an LDH release assay. Results Absorbance values(A values)for EBV LMP2-specific IgG and IgA antibodies in serum from mice immunized with the DNA vaccine and peptide vaccine were 1.573±0.025and 0.436±0.033,respectively,while A values for those antibodies in serum from mice immunized with the DNA vaccine alone were1.282±0.051and 0.317±0.022.The difference in A values was statistically significant(F=80.393,27.722,P0.05).However,A values for HPV L1-specific IgG were 0.648±0.063in mice immunized with the DNA vaccine and peptide vaccine but 0.702±0.023in mice immunized with the DNA vaccine alone.This difference in A values was not statistically significant(F=1.952,P0.05).A values for EBV LMP2-specific antibody subclasses IgG1and IgG2a were respectively 0.723±0.023and 0.594±0.084in mice immunized with the DNA vaccine alone,so these values did not differ significantly(F=6.643,P0.05)from those in the controls.In contrast,A values for EBV LMP2-specific antibody subclasses IgG1and IgG2awere respectively 0.897±0.042and 0.629±0.035in mice immunized with the DNA vaccine and peptide vaccine,so these values did differ significantly(F=72.306,P0.05)from those in the controls.At an effector-to-target cell(E:T)ratio of 10,the cytotoxicity(%)of splenocytes from mice immunized with the DNA and peptide vaccine was 27.70% while the cytotoxicity of splenocytes from mice immunized with the DNA vaccine alone was21.50%.The difference in cytotoxicity of splenocytes was statistically significant(F=51.559,P0.05). Conclusion Combined immunization with a DNA vaccine and peptide vaccine enhanced the cytotoxicity of splenocytes and it also induced a significant humoral immune response.This immunization strategy may provide a guide to immunotherapy for EBV-associated tumors.

[T Cells Recognizing EBV-epitopes Arose in Co-Culture of Peripheral Blood Mononuclear Cells from EB-infected Patients and Dendritic Cells Loaded with LMP2-mixed Peptides].

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

EBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein

Induction of the Epstein-Barr Virus Latent Membrane Protein 2 Antigen-specific Cytotoxic T Lymphocytes Using Human Leukocyte Antigen Tetramer-based Artificial Antigen-presenting Cells

Anti-nasopharyngeal carcinoma effect in vivo and in vitro of cytotoxicity T lymphocyte induced by Ad5-latent membrane protein 2A]

Induction of EBV Latent Membrane Protein-2A (Lmp2a)-Specific T Cells and Construction of Individualized TCR-engineered T Cells for EBV-associated Malignancies

Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders

In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus

[The Effect of Stimulation of Dendritic Cell on HBV-epitopic Cytotoxic T-lymphocyte].

[Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].

Study on Combined Immunization with a DNA Vaccine and a Peptide Vaccine Consisting of Multiple Epitopes of Latent Membrane Protein 2 from Epstein-Barr Virus

Cytotoxicity of specific CTL induced by EBV-LMP2A peptide on human EBV associated gastric carcinoma cell in vitro

Prokaryotic Expression and Antigen Characteristics of EB Virus Latent Membrane Protein 2 ( EBV-LMP2) Multi-Epitopes

[Assessment of Lymphocytic Function in Vitro Stimulated by Specific Tumor Polypeptide Combined with Dendritic Cells].

[Proliferation of Specific Cytotoxic T Lymphocytes Induced by Immunoglobulin Heavy Chain Framework Region-Derived Antigenic Nonapeptides].

Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

[The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].

DCs Pulsed with Novel HLA-A2-restricted CTL Epitopes Against Hepatitis C Virus Induced a Broadly Reactive Anti-Hcv-specific T Lymphocyte Response.

EBV Promotes Human CD8 NKT Cell Development.

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation